Abivax S.A.
ABVX • Biotechnology
$114.79
▲ +0.76 (+0.66%)
Current price
EarningsLatest report: Dec 31, 2025
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$7.98B
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.07Healthy liquidity · 8.75Weak profitability
Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Mar 23, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$114.79
Change0.66%
Shares Out69.53M
Market Cap$7.98B
52W Range7.64 - 148.83
Beta-0.20
P/E-20.56
P/S0.00
P/B15.19
P/FCF-44.34
EV/Sales0.00
EV/EBITDA-24.93
Price$114.79
Change0.66%
Shares Out69.53M
Market Cap$7.98B
52W Range7.64 - 148.83
Beta-0.20
P/E-20.56
P/S0.00
P/B15.19
P/FCF-44.34
EV/Sales0.00
EV/EBITDA-24.93
EV/FCF-48.10
Earnings Yield-4.86%
FCF Yield-2.26%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.07
Current Ratio8.75
Quick Ratio8.75
Revenue 5Y-100.00%
Target$152.71
Target Upside33.03%
Target Median$158.00
Target Range90.00 - 180.00
Volume4.48M
Avg Volume1.78M
EPS Surprise0.22
Investment DNA
How strong this company looks for long-term investors
34
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Manageable debt level · 0.07Healthy liquidity · 8.75Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 13 analyst votes · 2026-09-05
96/100
Bullish
Bullish
12
Hold
1
Bearish
0
Price Target
2026-07-02
Low
$90.00
Mean
$136.71
Median
$135.00
High
$175.00
🧾
No insider activity
No recent insider transactions available.